{
"info": {
"nct_id": "NCT05566457",
"official_title": "Clinical Study of Huangshi Guizhi Wuwu Decoction in Improving the Paclitaxel-related Neurotoxicity in Breast Cancer Patients",
"inclusion_criteria": "Healthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "The inclusion criteria comprised:\n\nˑ histologically confirmed untreated BC; ˑ female; ˑage from 18 to 65 years old; ( ˑ Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; ˑat least receiving 4 cycles of nab-PTX (260mg/m2); ˑ grade 2 or greater nab-PTX induced-PN evaluated by European Organisation for the Research and Treatment of Cancer-Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20)(12, 13); ˑ estimated survival time > 6 months. The exclusion criteria were: ˑ a history of diabetes or neurological disorders; ˑmental disorder; ˑabnormal hepatic functions (total bilirubin upper limit of normal (ULN), alanine transaminase/aspartate transaminase ≥ 2.5 × ULN ), renal functions(creatinine ≥ 1.5 × ULN), and hematological functions (absolute neutrophil count ≤ 1.5 × 109/L, platelet count ≤ 80 × 109/L, hemoglobin < 90 g/L); ˑFailure to complete chemotherapy due to treatment-related adverse events; ˑ a family history of a genetic neuropathy; ˑhad received previous treatment with neurotoxic chemotherapy, including oxaliplatin, cisplatin, vinca alkaloid and etc.; ˑ a history of allergy to Chinese medicine."
},
"inclusion_lines": [
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "female"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "female"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
},
{
"identified_line": {
"line": "Must have maximum age of 65 Years",
"criterions": [
{
"exact_snippets": "maximum age of 65 Years",
"criterion": "age",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 65,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "maximum age of 65 Years",
"criterion": "age",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 65,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"identified_line": {
"line": "The inclusion criteria comprised:",
"criterions": []
},
"logical_structure": {
"and_criteria": []
}
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": [
{
"identified_line": {
"line": "ˑ histologically confirmed untreated BC; ˑ female; ˑage from 18 to 65 years old; ( ˑ Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; ˑat least receiving 4 cycles of nab-PTX (260mg/m2); ˑ grade 2 or greater nab-PTX induced-PN evaluated by European Organisation for the Research and Treatment of Cancer-Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20)(12, 13); ˑ estimated survival time > 6 months. The exclusion criteria were: ˑ a history of diabetes or neurological disorders; ˑmental disorder; ˑabnormal hepatic functions (total bilirubin upper limit of normal (ULN), alanine transaminase/aspartate transaminase ≥ 2.5 × ULN ), renal functions(creatinine ≥ 1.5 × ULN), and hematological functions (absolute neutrophil count ≤ 1.5 × 109/L, platelet count ≤ 80 × 109/L, hemoglobin < 90 g/L); ˑFailure to complete chemotherapy due to treatment-related adverse events; ˑ a family history of a genetic neuropathy; ˑhad received previous treatment with neurotoxic chemotherapy, including oxaliplatin, cisplatin, vinca alkaloid and etc.; ˑ a history of allergy to Chinese medicine.",
"criterions": [
{
"exact_snippets": "histologically confirmed untreated BC",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "confirmation",
"expected_value": "histologically confirmed"
}
},
{
"exact_snippets": "histologically confirmed untreated BC",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "treatment status",
"expected_value": "untreated"
}
},
{
"exact_snippets": "female",
"criterion": "gender",
"requirement": {
"requirement_type": "gender",
"expected_value": "female"
}
},
{
"exact_snippets": "age from 18 to 65 years old",
"criterion": "age",
"requirement": {
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
},
{
"operator": "<=",
"value": 65,
"unit": "years"
}
]
}
}
},
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "score",
"expected_value": {
"comparisons": [
{
"operator": "=",
"value": 0,
"unit": "N/A"
},
{
"operator": "=",
"value": 1,
"unit": "N/A"
}
]
}
}
},
{
"exact_snippets": "at least receiving 4 cycles of nab-PTX (260mg/m2)",
"criterion": "nab-PTX treatment",
"requirement": {
"requirement_type": "cycles",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "cycles"
}
}
},
{
"exact_snippets": "grade 2 or greater nab-PTX induced-PN evaluated by European Organisation for the Research and Treatment of Cancer-Chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20)",
"criterion": "nab-PTX induced peripheral neuropathy",
"requirement": {
"requirement_type": "grade",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "N/A"
}
}
},
{
"exact_snippets": "estimated survival time > 6 months",
"criterion": "estimated survival time",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 6,
"unit": "months"
}
}
},
{
"exact_snippets": "a history of diabetes or neurological disorders",
"criterion": "history of diabetes or neurological disorders",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "mental disorder",
"criterion": "mental disorder",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "abnormal hepatic functions (total bilirubin upper limit of normal (ULN), alanine transaminase/aspartate transaminase ≥ 2.5 × ULN )",
"criterion": "hepatic functions",
"requirement": {
"requirement_type": "total bilirubin",
"expected_value": "within normal limits"
}
},
{
"exact_snippets": "abnormal hepatic functions (total bilirubin upper limit of normal (ULN), alanine transaminase/aspartate transaminase ≥ 2.5 × ULN )",
"criterion": "hepatic functions",
"requirement": {
"requirement_type": "alanine transaminase/aspartate transaminase",
"expected_value": {
"operator": "<",
"value": 2.5,
"unit": "ULN"
}
}
},
{
"exact_snippets": "renal functions(creatinine ≥ 1.5 × ULN)",
"criterion": "renal functions",
"requirement": {
"requirement_type": "creatinine",
"expected_value": {
"operator": "<",
"value": 1.5,
"unit": "ULN"
}
}
},
{
"exact_snippets": "hematological functions (absolute neutrophil count ≤ 1.5 × 109/L, platelet count ≤ 80 × 109/L, hemoglobin < 90 g/L)",
"criterion": "hematological functions",
"requirement": {
"requirement_type": "absolute neutrophil count",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "× 109/L"
}
}
},
{
"exact_snippets": "hematological functions (absolute neutrophil count ≤ 1.5 × 109/L, platelet count ≤ 80 × 109/L, hemoglobin < 90 g/L)",
"criterion": "hematological functions",
"requirement": {
"requirement_type": "platelet count",
"expected_value": {
"operator": ">",
"value": 80,
"unit": "× 109/L"
}
}
},
{
"exact_snippets": "hematological functions (absolute neutrophil count ≤ 1.5 × 109/L, platelet count ≤ 80 × 109/L, hemoglobin < 90 g/L)",
"criterion": "hematological functions",
"requirement": {
"requirement_type": "hemoglobin",
"expected_value": {
"operator": ">=",
"value": 90,
"unit": "g/L"
}
}
},
{
"exact_snippets": "Failure to complete chemotherapy due to treatment-related adverse events",
"criterion": "completion of chemotherapy",
"requirement": {
"requirement_type": "completion",
"expected_value": true
}
},
{
"exact_snippets": "a family history of a genetic neuropathy",
"criterion": "family history of genetic neuropathy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "had received previous treatment with neurotoxic chemotherapy, including oxaliplatin, cisplatin, vinca alkaloid and etc.",
"criterion": "previous treatment with neurotoxic chemotherapy",
"requirement": {
"requirement_type": "treatment history",
"expected_value": false
}
},
{
"exact_snippets": "a history of allergy to Chinese medicine",
"criterion": "allergy to Chinese medicine",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
}
]
}